Private Equity

Updated:

Petri

Petri develops companies attacking the world’s largest problems at the frontier of biology and engineering. | Petri is a new approach for funding...

Petri logo

Petri

Petri develops companies attacking the world’s largest problems at the frontier of biology and engineering. | Petri is a new approach for funding formation-stage startups at the intersection of biology and engineering.

General information

Firm type

Private Equity

Year founded

2019

AUM

Undisclosed

Location

Region

North America

Country

United States

City

Boston

Corporate office

Boston, MA, United States

Principals

Tony Kulesa

Co-founder

Jamie Goldstein

Co-founder

Russ Wilcox

Co-founder

Sector focus

BiotechAI/MLClimateTechAgriTech & FoodTech

Frequently asked questions

Who runs investment decisions at Petri?

Tony Kulesa serves as the primary operating principal and leads investment decisions alongside co-founders Jamie Goldstein and Russ Wilcox. The three collectively manage the firm's pipeline and portfolio support, with Kulesa acting as the main interface for founders in the program.

How does Petri source proprietary deal flow?

Petri sources through its own community-building programs — Frequency Bio, virtual summits, and the Petri Podcast — which act as top-of-funnel engines attracting bioengineering PhDs, postdocs, and early-career scientists. The firm's connection to Pillar VC and Boston's university ecosystem provides additional proprietary access to talent before they formally enter venture markets.

Is Petri structured as a venture capital firm or a studio?

Petri operates as a hybrid: a pre-seed venture firm with a studio-like support layer. Unlike traditional biotech VCs that invest and observe, Petri embeds founders in a structured program offering mentorship, customer introductions, talent recruiting, and intellectual property guidance alongside capital. This makes it functionally closer to a company builder than a conventional fund.

Does Petri participate in fund commitments or only direct deals?

Petri only makes direct pre-seed investments in newly forming biotech companies. There is no evidence of any fund-of-funds activity or investment in external venture vehicles.

What investment stages does Petri target?

Petri exclusively targets pre-seed companies. The firm works with founders at the earliest stage — often before incorporation — to develop scientific ideas into fundable companies, covering the gap between academic research and institutional seed rounds.

How is Petri related to Pillar VC?

Petri was co-founded and is funded by Pillar VC, a Boston-based venture firm whose partners include the CEOs of Exact Sciences, Ginkgo Bioworks, and Iora Health. Petri draws on Pillar's operator network and resources but operates as a distinct entity focused exclusively on pre-seed bioengineering.

What is Petri's known posture on co-investments alongside external GPs?

Petri has not publicly disclosed a co-investment policy. Given its pre-seed focus and studio-like model, portfolio companies typically raise subsequent rounds from external biotech and deep-tech VCs, but no formal co-investment program has been documented.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Boston Private Equity profiles